Intellipharmaceutics International Inc. (IPCIF)

OTCMKTS: IPCIF · Delayed Price · USD
0.0579
0.00 (0.00%)
Feb 16, 2024, 12:52 PM EST - Market closed
Market Cap 1.86M
Revenue (ttm) 904,946
Net Income (ttm) -3.17M
Shares Out 35.00M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,630
Open 0.0579
Previous Close 0.0579
Day's Range 0.0579 - 0.0579
52-Week Range 0.0100 - 0.1100
Beta 0.30
Analysts n/a
Price Target n/a
Earnings Date n/a

About IPCIF

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 11
Stock Exchange OTCMKTS
Ticker Symbol IPCIF
Full Company Profile

Financial Performance

In 2022, IPCIF's revenue was $65,728, a change of 0.00% compared to the previous year's $65,728. Losses were -$2.89 million, 0.00% compared to 2021.

Financial Statements

News

Intellipharmaceutics International Inc. Announces Stock Option Grant

TORONTO, ON / ACCESSWIRE / February 8, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...

17 days ago - Accesswire

Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange

TORONTO, ON / ACCESSWIRE / January 2, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the r...

7 weeks ago - Accesswire

Intellipharmaceutics Announces Third Quarter 2023 Results

TORONTO, ON / ACCESSWIRE / October 16, 2023 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...

4 months ago - Accesswire

Intellipharmaceutics Reports Director Election Results

TORONTO, ON / ACCESSWIRE / September 14, 2023 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the ...

5 months ago - Accesswire

Intellipharmaceutics Announces Second Quarter 2023 Results

TORONTO, ON / ACCESSWIRE / July 14, 2023 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the re...

8 months ago - Accesswire

Intellipharmaceutics Announces Third Quarter 2022 Results

TORONTO, ON / ACCESSWIRE / October 14, 2022 / - Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the ...

1 year ago - Accesswire

Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets

TORONTO, ON / ACCESSWIRE / August 16, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the res...

1 year ago - Accesswire

Intellipharmaceutics Announces Second Quarter 2022 Results

TORONTO, ON / ACCESSWIRE / July 21, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the resea...

1 year ago - Accesswire

Intellipharmaceutics Announces Delay in Filing Second Quarter Results Due July 15, 2022, The Financial Statements Will be Filed By July 21, 2022

TORONTO, ON / ACCESSWIRE / July 15, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the ...

1 year ago - Accesswire

Intellipharmaceutics Announces First Quarter 2022 Results

TORONTO, ON / ACCESSWIRE / April 14, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...

2 years ago - Accesswire

Intellipharmaceutics Announces Fiscal Year 2021 Results

TORONTO, ON / ACCESSWIRE / February 28, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in th...

2 years ago - Accesswire

Intellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead

TORONTO, ON / ACCESSWIRE / January 13, 2022 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in t...

2 years ago - Accesswire

Intellipharmaceutics Comments on Recent Trading Activity

TORONTO, ON / ACCESSWIRE / December 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF and TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in th...

2 years ago - Accesswire

Intellipharmaceutics Announces Third Quarter 2021 Results

TORONTO, ON / ACCESSWIRE / October 15, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in t...

2 years ago - Accesswire

Kim Spencer McPhee Barristers, P.C. Publishes This Notice of Certification and Notice of Hearing for Settlement Approval of the Intellipharmaceutics International Inc. Securities Class Action

TORONTO--(BUSINESS WIRE)--Kim Spencer McPhee Barristers, P.C. today announces a proposed securities class action settlement regarding Intellipharmaceutics International Inc. (“IPCI”). In 2019, a propo...

2 years ago - Business Wire

Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement

TORONTO, ON / ACCESSWIRE / April 22, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...

3 years ago - Accesswire

Intellipharmaceutics Announces First Quarter 2021 Results

TORONTO, ON / ACCESSWIRE / April 14, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the rese...

3 years ago - Accesswire

Intellipharmaceutics Announces Fiscal Year 2020 Results

TORONTO, ON / ACCESSWIRE / March 1, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the ...

3 years ago - Accesswire